New drugs target hypoxia response in tumors.
Garber
Ken
K
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors*; D015507:Drugs, Investigational / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D051793:Hypoxia-Inducible Factor 1; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D007191:Indazoles / Q000494:pharmacology / Q000627:therapeutic use; D009150:Mustard Compounds / Q000494:pharmacology / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D009687:Nuclear Proteins / Q000037:antagonists & inhibitors*; D010666:Phenylpropionates / Q000494:pharmacology / Q000627:therapeutic use; D019772:Topotecan / Q000494:pharmacology / Q000627:therapeutic use; D014157:Transcription Factors / Q000037:antagonists & inhibitors*; D014183:Transplantation, Heterologous
C492908:2-amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D015507:Drugs, Investigational; C497442:HIF1A protein, human; D051793:Hypoxia-Inducible Factor 1; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D007191:Indazoles; D009150:Mustard Compounds; D009687:Nuclear Proteins; D010666:Phenylpropionates; D014157:Transcription Factors; C090937:3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole; D019772:Topotecan